Valganciclovir has widely become the agent of choice for the prevention of cytomegalovirus in recipients of organ transplants. Optimal dosing is needed to achieve efficacy and avoid toxicity. For subjects at high risk of cytomegalovirus, it is strongly suggested that full-dose (based on renal function) valganciclovir be used. While low-dose valganciclovir appears to be efficacious in some repor...

To provide the best possible long-term outcomes for patients, a number of strategies have been proposed based on the possibility to switch from a successful protease inhibitor (PI)-based highly active antiretroviral therapy (HAART) to another antiretroviral regimen. The available evidence from clinical trials in virologically controlled patients demonstrates that switching the PI-based HAART to...